To determine the appropriate dose and units required for your patient, fill in patient weight, creatinine clearance, infusion length and the unit choice you will be using to administer Aggrastat®.
Aggrastat® Injection Premixed is supplied as a sterile solution in water for injection, for intravenous use, in 15 mL, 100 mL, and 250 mL single-use formats.
The recommended dosage is 25 mcg/kg administered intravenously within 5 minutes and then 0.15 mcg/kg/min for up to 18 hours.
Bolus(ml) All patients (using 250 mcg/mL bolus vial) | = 25 mcg/kg x body weight (kg) 250 mcg/mL |
Bolus(ml) All patients (using 50 mcg/mL units) | = 25 mcg/kg x body weight (kg) 50 mcg/mL |
Infusion (mL/h) Patients with CrCl>60mL/min (using 50 mcg/mL units) | = 0.15 mcg/kg/min x body weight (kg) x 60 min/h 50 mcg/mL |
Infusion (mL/h) Patients with CrCl≤60mL/min (using 50 mcg/mL units) | = 0.075 mcg/kg/min x body weight (kg) x 60 min/h 50 mcg/mL |
1. Bolus (Using 250 mcg/mL Bolus Vial)
2. Infusion (Using 50 mcg/mL Units)
Administer intravenously 25 mcg/kg within 5 minutes and then 0.15 mcg/kg/min for up to 18 hours. In patients with creatinine clearance (CrCl) ≤ 60 mL/min, give 25 mcg/kg bolus within 5 minutes followed by an infusion of 0.075 mcg/kg/min for up to 18 hours.
By using this resource, you agree to the following: This Dosing Calculator is being provided “AS IS” and is intended for use only by qualified healthcare providers. All calculations should be confirmed before use. Medicure makes no claims as to the accuracy of the information contained herein. The information being provided is not a substitute for clinical judgment. Neither Medicure, nor any other party involved in the preparation or publication of this site, shall be liable to you or others for any decisions made or actions taken by you or others in reliance on this information.
Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
For additional information, refer to the full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.FDA.gov/medwatch
or call 1-800-FDA-1088.
* This website is intended for U.S. healthcare professionals only.